-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance works better than either drug used alone in patients with chronic kidney disease (CKD) associated with type 2 diabetes.
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per share, looking for $150 million in proceeds and a valuation upwards of $1.1 billion. The specialist in delivering virtual treatment and support between doctor visits for people with chronic conditions like prediabetes, diabetes, musculoskeletal (MSK) conditions, and high blood pressure said that the offer is expected to close on Monday, with its shares trading on...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, which the company has said could be a blockbuster new indication for the drug. The European Commission has cleared a fixed-duration regimen of Calquence (acalabrutinib) in combination with AbbVie/Roche's BCL-2 inhibitor Venclexta (venetoclax) – with or without Roche's anti-CD20 drug Gazyva (obinutuzumab) – for previously untreated adult patients with CLL.
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News Indian pharma group Wockhardt has completed a pre-filing meeting with the FDA and hopes to submit its new antibiotic Zaynich in the US and Europe later this year, eyeing a possible launch in fiscal 2026/27. Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor called zidebactam that is designed to block a common antimicrobial resistance (AMR) mechanism and also has intrinsic antibacterial activity. It is being developed...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News Bankrupt genetic testing company 23andMe has said it wants to start a new round of bidding for its business after receiving a $305 million offer from a group led by founder and former chief executive Anne Wojcicki. The offer by Wojcicki's non-profit organisation TTAM Research Institute tops an earlier $256 million bid from Regeneron, which won the earlier auction process and was hoping to complete the takeover in the third quarter of this year. It was revealed earlier this week that...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
Using mRNA to stop HIV from hiding away in white blood cells could be the key to developing a way to eradicate the infection, rather than simply managing viral levels in the body. The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, who have used mRNA to force HIV to be mobilised from the reservoir of latent virus integrated into resting CD4-positive T lymphocytes in lab studies.
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth hormone deficiency, a condition diagnosed in up to 500 children a year. Sogroya (somapacitan), which can be administered as a once-weekly subcutaneous injection, has been recommended by health technology assessment (HTA) agency NICE for patients aged three to 17 with paediatric growth hormone deficiency in new guidance. The recommendation means that patients in England...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News Women who are taking weight-loss injections have been warned by the UK medicines regulator that they should make sure they are using effective contraception, due to concerns the drugs could harm unborn children. The Medicines and Healthcare products Regulatory Agency (MHRA) said while it is not known definitively that taking GLP-1 agonist medicines like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) can cause damage to foetuses in the womb, there is some...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
News New guidance from the EMA has introduced a shift in thinking at the regulator on the inclusion of pregnant and breastfeeding women in clinical trials. The new document, which is open for public consultation, represents "a change in paradigm" and recommends that including pregnant and breastfeeding subjects in clinical trials should be considered "for all medicines intended for people who can potentially give birth to children." At the moment, it is well recognised that pregnant and...
-
3 weeks ago | 
pharmaphorum.com | Phil Taylor
Brain-computer interface (BCI) developer Neuralink has completed a $650 million fifth-round financing that the company says will allow it to "bring our technology to more people."The injection of cash follows a period of rapid progress at the company, which began after it first implanted its N1 wireless chip into the brain of a human subject in January 2024.
